Vertex Advances VX-548 in Acute and Neuropathic Pain July 22, 2022 - VX-548 advances into pivotal development for people with acute pain; Phase 3 program to initiate in Q4 2022 - - Phase 2 dose-ranging trial in neuropathic pain expected to initiate by year end - -Breakthrough Therapy ...
Vertex Announces Publication of VX-548 Positive Phase 2, Proof-of-Concept Results in New England Journal of Medicine August 3, 2023 - First published manuscript of VX-548 preclinical and clinical trial results in a peer-reviewed journal - BOSTON--(BUSINESS WIRE)--Aug. 3, 2023-- Vertex ...